Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions

NCT02862145 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped 5 immune related serious adverse events in Phase 1 study

Conditions

Melanoma

Interventions

DRUG: MRX34
DRUG: Dexamethasone

Sponsor

Mirna Therapeutics, Inc.